Abstract
Fibrinolytic enzymes have received attention regarding their medicinal potential for thrombolytic diseases, a leading cause of morbidity and mortality worldwide. Various natural enzymes purified from animal, plant and microbial sources have been extensively studied. The aim of this work was to produce fibrinolytic protease by solid state fermentation using agro industrial substrates. Rhizopus arrhizus var. arrhizus UCP 1295 and Mucor subtillissimus UCP 1262 filamentous fungi species isolated from soil of Caatinga-PE, Brasil, were used as producer microorganisms. Wheat bran was shown to be the best substrate for the production of the enzyme and by using a 23 full factorial design the main effects and interactions of the quantity of the substrate wheat bran, moisture and temperature on the fibrinolytic enzyme production and protease were evaluated. The best results for fibrinolytic and protease activities, 144.58 U/mL and 48.33 U/mL, respectively, were obtained with Mucor subtillissimus UCP 1262 using as culture medium 3 g wheat bran, 50% moisture at a temperature of 25°C for 72 hours. The optimum temperature for the produced enzyme was 45°C and most of its original activity was retained after being subjected to 80°C for 120 min. The protease activity was enhanced by K+, Ca+ and Mn+; but with Cu+ there was an inhibition. The specificity to chromogenic substrate and the inhibition by PMSF indicates that it is a chymotrypsin-like serine protease. Presented results suggest that this enzyme produced by solid-state fermentation is an interesting alternative as a candidate for thrombolytic therapy.
Highlights
About 17.3 million people die each year of cardiovascular disease
The present study evaluates the production of fibrinolytic protease by Rhizopus arrhizus var. arrhizus UCP 1295 and Mucor subtillissimus UCP 1262 in solid-state fermentation using agroindustrial residues
The results presented for the production fibrinolytic protease by M. subtillissimus UCP 1262 using wheat bran as substrate was performed according to the Table 1
Summary
About 17.3 million people die each year of cardiovascular disease. It is estimated that in 2030 the number of deaths could reach 23.6 million [1]. Cardiovascular diseases include acute myocardial infarction, ischemic heart disease, valvular heart disease, peripheral vascular disease, arrhythmias, high blood pressure and stroke [2] [3]. These problems are usually caused by accumulation of fibrin (blood clots) that adhere to the blood vessels wall leading to thrombosis [4]. Fibrinolytic enzymes produced by microorganisms, have the potential to inhibit blood coagulation and are able to degrade the fibrin. Some potential microorganisms like bacteria of the genus Bacillus, cyanobacteria, fungi, and Streptomyces have been described as sources of fibrinolytic agents [5]-[9]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have